Should I buy or sell Repligen stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks .

What is Repligen's stock price target for 2024?

9 brokers have issued 12-month price objectives for Repligen's shares. Their RGEN share price targets range from $165.00 to $220.00. On average, they expect the company's stock price to reach $196.70 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts .

How have RGEN shares performed in 2024?

Repligen's stock was trading at $179.80 at the beginning of the year. Since then, RGEN stock has decreased by 12.4% and is now trading at $157.46. View the best growth stocks for 2024 here .

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our RGEN earnings forecast .

How can I listen to Repligen's earnings call?

Repligen will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "3623615".

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The biotechnology company earned $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a trailing twelve-month return on equity of 5.00%. Repligen's revenue for the quarter was down 16.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.68 EPS.

What ETFs hold Repligen's stock?

ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX) , Invesco Biotechnology & Genome ETF (PBE) , BlackRock Future Innovators ETF (BFTR) , BNY Mellon Innovators ETF (BKIV) , Fidelity Disruptive Medicine ETF (FMED) , VanEck Biotech ETF (BBH) , Nuveen ESG Mid-Cap Growth ETF (NUMG) and WisdomTree BioRevolution Fund (WDNA) .

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY24 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of $1.42-1.49 for the period, compared to the consensus earnings per share estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com . Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Salesforce (CRM) , Block (SQ) , Advanced Micro Devices (AMD) , DocuSign (DOCU) , Walt Disney (DIS) , Netflix (NFLX) , Tesla (TSLA) and ServiceNow (NOW) .

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.60%), Artemis Investment Management LLP (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.19%), Congress Asset Management Co. MA (0.16%), Azzad Asset Management Inc. ADV (0.04%) and State of Michigan Retirement System (0.02%). Insiders that own company stock include Anthony Hunt , Christine Gebski , James Bylund , Jon Snodgres , Karen A Dawes, Karen A Dawes , Manner Carrie Eglinton , Martin D Madaus , Nicolas Barthelemy , Ralf Kuriyel and Thomas F Ryan Jr . View institutional ownership trends .

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Repligen have any subsidiaries?

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC. Read More

Top-Rated StocksTop-Rated

NASDAQ:RGEN

Repligen (RGEN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free RGEN Stock Alerts

$157.09

+0.03 (+0.02%)

(As of 02:33 PM ET)

Compare

Today's Range: $156.55
▼
$159.41
50-Day Range: $157.06
▼
$208.42
52-Week Range: $110.45
▼
$211.13

Volume: 186,059 shs
Average Volume: 533,959 shs
Market Capitalization: $8.77 billion

P/E Ratio: 218.18
Dividend Yield: N/A
Price Target: $196.70

Get Repligen alerts:

Repligen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 24.9% Upside
$196.70 Price Target
Short Interest: Bearish
9.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.33
Upright™ Environmental Score
News Sentiment: 0.62
Based on 10 Articles This Week
Insider Trading: Selling Shares
$5.04 M Sold Last Quarter
Proj. Earnings Growth: 43.15%
From $1.46 to $2.09 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.76 out of 5 stars

Medical Sector

216th out of 918 stocks

Biological Products, Except Diagnostic Industry

25th out of 151 stocks

2.4

Analyst's Opinion

Consensus Rating
Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Repligen has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.18% of the float of Repligen has been sold short.
Short Interest Ratio / Days to Cover
Repligen has a short interest ratio ("days to cover") of 8.8.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Repligen does not currently pay a dividend.
Dividend Growth
Repligen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Repligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.
Environmental Sustainability
The Environmental Impact score for Repligen is -1.33.

2.6

News and Social Media Coverage

News Sentiment
Repligen has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Repligen this week, compared to 5 articles on an average week.
Search Interest
2 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,039,532.00 in company stock.
Percentage Held by Insiders
Only 1.20% of the stock of Repligen is held by insiders.
Percentage Held by Institutions
97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Repligen are expected to grow by 43.15% in the coming year, from $1.46 to $2.09 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Repligen is 218.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 137.39.
Price to Earnings Ratio vs. Sector
The P/E ratio of Repligen is 218.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 190.30.
Price to Earnings Growth Ratio
Repligen has a PEG Ratio of 5.27. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Repligen has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Repligen Stock (NASDAQ:RGEN)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RGEN Stock News Headlines

April 18, 2024 | nasdaq.com

Repligen Corporation Common Stock (RGEN)

April 17, 2024 | finance.yahoo.com

Repligen to Report First Quarter 2024 Financial Results

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 17, 2024 | nasdaq.com

Notable Two Hundred Day Moving Average Cross - RGEN

April 16, 2024 | americanbankingnews.com

Cardiff Oncology (NASDAQ:CRDF) and Repligen (NASDAQ:RGEN) Critical Contrast

April 15, 2024 | americanbankingnews.com

Critical Review: Repligen (NASDAQ:RGEN) vs. Neurocrine Biosciences (NASDAQ:NBIX)

April 12, 2024 | finance.yahoo.com

Artisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share Appreciation

April 12, 2024 | americanbankingnews.com

Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 9, 2024 | markets.businessinsider.com

RBC Capital Remains a Buy on Repligen (RGEN)

March 19, 2024 | globenewswire.com

Repligen Appoints Maggie A. Pax to Board of Directors

March 18, 2024 | finance.yahoo.com

Are Repligen Corporation's (NASDAQ:RGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

March 16, 2024 | finance.yahoo.com

RGEN Apr 2024 150.000 call

March 12, 2024 | finance.yahoo.com

Repligen Corp CEO Anthony Hunt Sells 16,707 Shares

February 28, 2024 | morningstar.com

Repligen Corp RGEN

February 27, 2024 | finance.yahoo.com

Repligen Corp COO James Bylund Sells 4,373 Shares

February 26, 2024 | finance.yahoo.com

Estimating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

February 24, 2024 | msn.com

Repligen (RGEN) Price Target Increased by 8.15% to 203.98

February 24, 2024 | finance.yahoo.com

Decoding Repligen Corp (RGEN): A Strategic SWOT Insight

February 22, 2024 | benzinga.com

Repligen Stock (NASDAQ:RGEN), Short Interest Report

February 22, 2024 | finance.yahoo.com

Repligen Corporation (NASDAQ:RGEN) Q4 2023 Earnings Call Transcript

February 21, 2024 | msn.com

What's Going On With Life Science-Focused Repligen Stock Today?

February 21, 2024 | finance.yahoo.com

Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates

February 21, 2024 | finanznachrichten.de

Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 | finance.yahoo.com

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 | finance.yahoo.com

Repligen Corp (RGEN) Reports Decline in 2023 Revenue and Net Income

February 21, 2024 | globenewswire.com

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

See More Headlines

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:RGEN
CUSIP: 75991610
CIK: 730272
Web: www.repligen.com
Phone: (781) 250-0111
Fax: 781-250-0115
Employees: 1,783
Year Founded: 1981

Price Target and Rating

Average Stock Price Target: $196.70
High Stock Price Target: $220.00
Low Stock Price Target: $165.00
Potential Upside/Downside: +25.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.72
Trailing P/E Ratio: 218.18
Forward P/E Ratio: 107.60
P/E Growth: 5.27
Net Income: $41.58 million
Net Margins: 6.51%
Pretax Margin: 10.04%
Return on Equity: 5.00%
Return on Assets: 3.78%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 7.02
Quick Ratio: 5.75

Sales & Book Value

Annual Sales: $638.76 million
Price / Sales: 13.73
Cash Flow: $2.95 per share
Price / Cash Flow: 53.20
Book Value: $35.31 per share
Price / Book: 4.45

Miscellaneous

Outstanding Shares: 55,839,000
Free Float: 55,169,000
Market Cap: $8.77 billion
Optionable: Optionable
Beta: 1.02

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Anthony J. Hunt (Age 60)
CEO & Director
Comp: $885k
Mr. Olivier Loeillot (Age 54)
President & Chief Commercial Officer
Comp: $1.49M
Mr. Jason K. Garland (Age 50)
Chief Financial Officer
Comp: $282.99k
Mr. James R. Bylund (Age 60)
Chief Operating Officer
Comp: $472.18k
Ms. Christine Gebski (Age 56)
Senior Vice President of Filtration & Chromatography
Comp: $396.09k
Mr. Ralf Kuriyel (Age 66)
Senior Vice President of Research & Development
Comp: $401.74k
Mr. Keith Lee Robinson
Chief Information Officer
Ms. Sondra S. Newman
Global Head of Investor Relations
Ms. Kimberly A. Cornwell
General Counsel
Dr. Jaime M. Humara Ph.D.
Senior Vice President of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Repligen stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.
What is Repligen's stock price target for 2024?: 9 brokers have issued 12-month price objectives for Repligen's shares. Their RGEN share price targets range from $165.00 to $220.00. On average, they expect the company's stock price to reach $196.70 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.
How have RGEN shares performed in 2024?: Repligen's stock was trading at $179.80 at the beginning of the year. Since then, RGEN stock has decreased by 12.4% and is now trading at $157.46.
View the best growth stocks for 2024 here.
When is Repligen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our RGEN earnings forecast.
How can I listen to Repligen's earnings call?: Repligen will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "3623615".
How were Repligen's earnings last quarter?: Repligen Co. (NASDAQ:RGEN) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The biotechnology company earned $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a trailing twelve-month return on equity of 5.00%. Repligen's revenue for the quarter was down 16.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.68 EPS.
What ETFs hold Repligen's stock?: ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG) and WisdomTree BioRevolution Fund (WDNA).

What guidance has Repligen issued on next quarter's earnings?: Repligen issued an update on its FY24 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of $1.42-1.49 for the period, compared to the consensus earnings per share estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million.
What is Tony J. Hunt's approval rating as Repligen's CEO?: 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Repligen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).
Who are Repligen's major shareholders?: Repligen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.60%), Artemis Investment Management LLP (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.19%), Congress Asset Management Co. MA (0.16%), Azzad Asset Management Inc. ADV (0.04%) and State of Michigan Retirement System (0.02%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.
How do I buy shares of Repligen?: Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Repligen have any subsidiaries?: The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More

This page (NASDAQ:RGEN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Repligen (RGEN) Stock Price, News & Analysis

Repligen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Repligen Stock (NASDAQ:RGEN)

RGEN Stock Price History

RGEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

RGEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™